Minimally Invasive Blood Glucose Sensor

Information

  • Research Project
  • 6585041
  • ApplicationId
    6585041
  • Core Project Number
    R43DK063776
  • Full Project Number
    1R43DK063776-01
  • Serial Number
    63776
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/15/2003 - 21 years ago
  • Project End Date
    2/28/2004 - 20 years ago
  • Program Officer Name
    HEART, LUNG, AND BLOOD INST., NATIONAL
  • Budget Start Date
    3/15/2003 - 21 years ago
  • Budget End Date
    2/28/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Minimally Invasive Blood Glucose Sensor

DESCRIPTION (provided by applicant): The overall aim of this research is to develop a micro-amperometric, minimally invasive, self-compensating, biosensor to continuously monitor blood glucose levels of diabetic patients, with specific attention to monitoring hypoglycemia. One of the primary limitations in many current Continuous Glucose Monitoring System sensors is their susceptibility to biofouling and encapsulation, which causes interference, drift and inaccuracies in reported blood glucose levels. The proposed glucose biosensor consists of a small diameter precious metal wire with a thin film of glucose oxidase immobilized on its surface, and a diffusion limiting, biocompatible membrane overcoat. This sensor will have a rapid and linear response over a wide dynamic range, be stable, readily replaced by a lay user, and will have a low cost disposable sensor element. Under Phase I the sensor configuration will be optimized and a linear response at concentrations up to 400 mg/dL in buffer solution, serum, and stability for at least 24 hours, sensor output repeatability, and the ability to inherently compensate for the effects of biofouling and encapsulation will be demonstrated. The major innovations present in this proposed development include the self-compensation feature; the use of a multilayer membrane structure to reduce interference; and the use of biocompatible diffusion limiting coatings to minimize biofouling and sensor encapsulation. Preliminary testing conducted under internal funding has shown preliminary sensor feasibility in buffer solution. Once the sensor configuration has been optimized and met the Phase I demonstration criteria, more detailed Phase II development and testing are planned.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    107560
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:107560\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOHAWK INNOVATIVE TECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
    883926594
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122052033
  • Organization District
    UNITED STATES